---
company: HEALTHPEAK PROPERTIES, INC.
ticker: DOC
form: 8-K
filed: 2026-08-04
accession: 0001628280-26-052608
source: https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/
---

# Healthpeak Properties (DOC) earnings release, August 4, 2026

Healthpeak Properties, Inc. (DOC) · Form 8-K, Item 2.02 · Filed 2026-08-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/765880/000162828026052608/)

Healthpeak Properties Reports Second Quarter 2026 Results and Increases Full Year 2026 Earnings Guidance

DENVER, August 4, 2026 -

Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended June 30, 2026.

SECOND QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.08 per share and FFO as Adjusted of $0.46 per share – Second quarter Outpatient Medical and Lab new and renewal lease executions totaled 1.6 million square feet:

• Outpatient Medical new lease executions totaled 327,000 square feet and renewal lease executions totaled 916,000 square feet

◦ Subsequent to the second quarter, we have entered into approximately 204,000 square feet of Outpatient Medical leases and have another approximately 882,000 under signed letters of intent ("LOIs")

• Lab new lease executions totaled 222,000 square feet and renewal lease executions totaled 159,000 square feet

◦ Subsequent to the second quarter, we have entered into approximately 20,000 square feet of Lab leases and have another approximately 480,000 square feet under signed LOIs – Total occupancy increased sequentially by +20 basis points ("bps") in Outpatient Medical to 90.7% and by +80 bps in Lab to 78.5% – Janus Living (NYSE: JAN) reported year-over-year revenue and Adjusted EBITDAre growth of 45% and 34%, respectively – Entered into a new $20 million outpatient medical development agreement to support Northside Hospital’s continued expansion in the Atlanta market – Generated $1.4 billion of proceeds from Outpatient Medical recapitalizations, seller financing loan repayments, and dispositions during the second quarter and through August 3, bringing year-to-date proceeds to $1.75 billion

• As previously disclosed, in July 2026, closed on the recapitalization and sale of a 49% joint venture interest in an 86-asset, 5.6 million square foot outpatient medical portfolio to affiliates of Brookfield at a gross valuation of $2.1 billion, generating proceeds of approximately $1.025 billion – Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended June 30, 2026 – Authorized new $500 million share repurchase program – Published 15 th annual Corporate Impact Report highlighting Healthpeak's continued focus on building a resilient portfolio, advancing sustainability goals, fostering a workplace culture guided by our WE CARE core values, and promoting sound corporate governance and transparency

To learn more and view the Corporate Impact Report, please visit www.healthpeak.com/corporate-impact

SECOND QUARTER RESULTS

Page 1

Page 2

JANUS LIVING SECOND QUARTER FINANCIAL AND OPERATING HIGHLIGHTS

• Revenue of $216 million, up 45% compared to the prior year quarter

• Adjusted EBITDAre of $79 million, up 34% compared to the prior year quarter

• Total Adjusted Net Operating Income of $58 million, up 37% compared to the prior year quarter

◦ Same-store Adjusted NOI increased 19.2% and margin expanded 250 basis points

• During the second quarter, acquired two senior housing communities for approximately $105 million

• Subsequent to quarter end, and through August 3, 2026, completed approximately $1.0 billion of senior housing acquisitions

• As of August 3, 2026, and subsequent to closing the acquisitions referenced above, Janus Living had approximately $558 million of unrestricted cash and no outstanding debt

• Under purchase agreement for approximately $59 million incremental senior housing acquisition

Janus Living, Inc. is a pure-play senior housing real estate investment trust that owns high-quality communities across the United States, and is majority owned by Healthpeak. Healthpeak owns 214.7 million shares of Janus Living common stock and operating partnership common units, representing a 73.6% equity ownership as of June 30, 2026. Janus Living is consolidated into Healthpeak’s financial statements, with the approximately 26.4% not owned by Healthpeak reported as noncontrolling interest.

NORTHSIDE OUTPATIENT MEDICAL DEVELOPMENT

In June 2026, Healthpeak entered into a development agreement for a new $20 million, 33,000 square foot outpatient medical building in the Sugar Hill submarket of Atlanta, Georgia.

The development is 84% pre-leased to Northside Hospital and affiliated physician groups supporting a range of clinical services and extends Northside’s network in a high-growth submarket connecting its Forsyth and Gwinnett hospital campuses.

The development represents Healthpeak’s fifth ground-up project totaling 565,000 square feet supporting Northside Hospital’s continued outpatient expansion in the Atlanta market.

OUTPATIENT MEDICAL JOINT VENTURE RECAPITALIZATION

As previously disclosed, in July 2026, Healthpeak entered into a joint venture with affiliates of Brookfield Asset Management (“Brookfield”) through the contribution of an 86-property outpatient medical portfolio valued at approximately $2.1 billion. The portfolio comprises approximately 5.6 million square feet and is located across 11 states including Kentucky, Indiana, Pennsylvania, Arkansas, Illinois, Minnesota, New Jersey, and New York. The portfolio is 95% leased with a weighted average remaining lease term of six years.

Under the terms of the joint venture, Brookfield owns a 49% non-controlling equity interest and Healthpeak retains a 51% interest in the joint venture and serves as managing member, providing asset and property management services and earning customary fees.... (truncated)return excluding initial transaction expenses.

The joint venture advances Healthpeak’s capital allocation strategy by generating proceeds to strengthen its balance sheet, fund investment opportunities, and support long-term growth. The transaction establishes a structure by which the parties can expand their relationship over time and also underscores the differentiated platform Healthpeak has built, including deep health system relationships and ongoing investments across the enterprise in technology, systems, and innovation that enhance long-term portfolio performance.

SELLER FINANCING LOAN REPAYMENT AND OTHER DISPOSITIONS

In June 2026, Healthpeak received approximately $400 million of gross proceeds from the partial repayment of a seller financing loan. The remaining $20 million loan balance was extended by 12 months pursuant to contractual extension rights. The repayment resulted in a one-time $9 million increase in interest income from the accelerated recognition of the remaining fair value discount.

During the second quarter of 2026, Healthpeak closed on $40 million of non-core outpatient medical dispositions at

Page 3 a trailing cash capitalization rate of 4.9%.

## Financial statements

### Income Statement (Three Months Ended June 30, — In thousands, except per share data)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues: | Rental and related revenues | 533,354 | 529,687 | 1,071,790 | 1,067,828 |
| Revenues: | Resident fees and services | 216,456 | 148,855 | 416,801 | 297,782 |
| Revenues: | Interest income and other | 21,769 | 15,806 | 35,940 | 31,627 |
| Revenues: | Total revenues | 771,579 | 694,348 | 1,524,531 | 1,397,237 |
| Costs and expenses: | Operating | 333,123 | 276,181 | 656,984 | 549,324 |
| Costs and expenses: | Depreciation and amortization | 283,390 | 265,916 | 573,124 | 534,462 |
| Costs and expenses: | Interest expense | 92,280 | 75,063 | 179,572 | 147,756 |
| Costs and expenses: | General and administrative | 22,517 | 20,764 | 47,108 | 46,882 |
| Costs and expenses: | Transaction costs | 9,172 | 10,215 | 33,321 | 15,749 |
| Costs and expenses: | Impairments and loan loss reserves (recoveries), net | -1,479 | 3,499 | -3,754 | -63 |
| Costs and expenses: | Total costs and expenses | 739,003 | 651,638 | 1,486,355 | 1,294,110 |
| Other income (expense): | Gain (loss) on sales of real estate, net | 9,988 | 1,636 | 60,657 | 1,636 |
| Other income (expense): | Gain (loss) on debt extinguishments |  |  | -403 |  |
| Other income (expense): | Other income (expense), net | 16,766 | -4,692 | 156,545 | -10,818 |
| Other income (expense): | Total other income (expense), net | 26,754 | -3,056 | 216,799 | -9,182 |
| Other income (expense): | Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 59,330 | 39,654 | 254,975 | 93,945 |
| Other income (expense): | Income tax benefit (expense) | 1,402 | -2,382 | 1,148 | -4,462 |
| Other income (expense): | Equity income (loss) from unconsolidated joint ventures | 2,509 | 1,747 | 6,774 | -400 |
| Other income (expense): | Net income (loss) | 63,241 | 39,019 | 262,897 | 89,083 |
| Other income (expense): | Noncontrolling interests’ share in earnings | -10,423 | -7,346 | -16,446 | -14,582 |
| Other income (expense): | Net income (loss) attributable to Healthpeak Properties, Inc. | 52,818 | 31,673 | 246,451 | 74,501 |
| Other income (expense): | Participating securities’ share in earnings | -150 | -115 | -299 | -579 |
| Other income (expense): | Net income (loss) applicable to common shares | 52,668 | 31,558 | 246,152 | 73,922 |
| Earnings per common share: | Basic | 0.08 | 0.05 | 0.36 | 0.11 |
| Earnings per common share: | Diluted | 0.08 | 0.05 | 0.36 | 0.11 |
| Weighted average shares outstanding: | Basic | 689,885 | 695,188 | 692,508 | 697,117 |
| Weighted average shares outstanding: | Diluted | 689,885 | 695,194 | 692,843 | 697,146 |

### Income Statement (Three Months Ended June 30, — In thousands, except per share data)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income (loss) applicable to common shares | 52,668 | 31,558 | 246,152 | 73,922 |
| Real estate related depreciation and amortization | 283,390 | 265,916 | 573,124 | 534,462 |
| Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 7,644 | 12,530 | 14,856 | 24,730 |
| Noncontrolling interests’ share of real estate related depreciation and amortization | -15,421 | -4,426 | -20,123 | -8,879 |
| Loss (gain) on sales of depreciable real estate, net | -9,988 | -1,636 | -60,657 | -1,636 |
| Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures | 1,793 |  | 1,793 |  |
| Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net | 973 |  | 973 |  |
| Loss (gain) upon change of control, net(1) | -226 |  | -138,343 |  |
| Taxes associated with real estate dispositions | -1,863 | -335 | -1,805 | -335 |
| Nareit FFO applicable to common shares | 318,970 | 303,607 | 615,970 | 622,264 |
| Distributions on dilutive convertible units and other | 4,384 | 4,560 | 8,930 | 9,183 |
| Diluted Nareit FFO applicable to common shares | 323,354 | 308,167 | 624,900 | 631,447 |
| Diluted Nareit FFO per common share | 0.46 | 0.43 | 0.88 | 0.89 |
| Weighted average shares outstanding - Diluted Nareit FFO | 704,472 | 709,839 | 707,066 | 711,828 |
| Impact of adjustments to Nareit FFO: | Transaction, merger, and restructuring-related costs(2) | 7,734 | 10,215 | 28,302 | 15,749 |
| Impact of adjustments to Nareit FFO: | Other impairments (recoveries) and other losses (gains), net(3) | -1,479 | 3,499 | -3,754 | 179 |
| Impact of adjustments to Nareit FFO: | Loss (gain) on debt extinguishments |  |  | 302 |  |
| Impact of adjustments to Nareit FFO: | Casualty-related charges (recoveries), net(4) | -4,191 | 3,919 | -4,381 | 8,145 |
| Impact of adjustments to Nareit FFO: | Recognition (reversal) of valuation allowance on deferred tax assets(5) |  |  | -3,058 |  |
| Impact of adjustments to Nareit FFO: | Total adjustments | 2,064 | 17,633 | 17,411 | 24,073 |
| Impact of adjustments to Nareit FFO: | FFO as Adjusted applicable to common shares | 321,034 | 321,240 | 633,381 | 646,337 |
| Impact of adjustments to Nareit FFO: | Distributions on dilutive convertible units and other | 4,382 | 4,545 | 8,916 | 9,161 |
| Impact of adjustments to Nareit FFO: | Diluted FFO as Adjusted applicable to common shares | 325,416 | 325,785 | 642,297 | 655,498 |
| Impact of adjustments to Nareit FFO: | Diluted FFO as Adjusted per common share | 0.46 | 0.46 | 0.91 | 0.92 |
| Impact of adjustments to Nareit FFO: | Weighted average shares outstanding - Diluted FFO as Adjusted | 704,472 | 709,839 | 707,066 | 711,828 |
| Other operating data: | Amortization of deferred financing costs and debt discounts (premiums) | 8,900 | 7,875 | 17,264 | 15,727 |
| Other operating data: | Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization | 12,866 | 19,042 | 20,621 | 23,739 |
| Other operating data: | Stock-based compensation amortization expense | 4,351 | 1,738 | 8,853 | 6,365 |

### Balance Sheet (In thousands, except share and per share data)

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Real estate: | Buildings and improvements | 17,211,536 | 16,593,535 |
| Real estate: | Development costs and construction in progress | 969,495 | 1,010,657 |
| Real estate: | Land and improvements | 3,225,957 | 3,007,346 |
| Real estate: | Accumulated depreciation | -4,543,382 | -4,512,443 |
| Real estate: | Net real estate | 16,863,606 | 16,099,095 |
| Real estate: | Loans receivable, net of reserves of $8,165 and $11,345 | 261,398 | 606,020 |
| Real estate: | Investments in unconsolidated joint ventures | 526,780 | 802,601 |
| Real estate: | Accounts receivable, net of allowance of $3,523 and $2,018 | 72,134 | 78,327 |
| Real estate: | Cash and cash equivalents | 1,626,827 | 467,457 |
| Real estate: | Restricted cash | 91,858 | 70,245 |
| Real estate: | Intangible assets | 717,494 | 654,516 |
| Real estate: | Assets held for sale | 37,101 | 80,621 |
| Real estate: | Right-of-use asset | 395,124 | 412,198 |
| Real estate: | Deferred tax assets | 122,320 | 111,248 |
| Real estate: | Goodwill | 68,529 | 68,529 |
| Real estate: | Other assets | 896,875 | 885,161 |
| Real estate: | Total assets | 21,680,046 | 20,336,018 |
| Liabilities and Equity | Bank line of credit and commercial paper | 1,495,994 | 1,078,850 |
| Liabilities and Equity | Term loans | 1,646,282 | 1,647,113 |
| Liabilities and Equity | Senior unsecured notes | 6,785,697 | 6,772,722 |
| Liabilities and Equity | Mortgage debt | 104,213 | 349,209 |
| Liabilities and Equity | Intangible liabilities | 155,466 | 173,697 |
| Liabilities and Equity | Liabilities related to assets held for sale | 594 | 11,900 |
| Liabilities and Equity | Lease liability | 288,194 | 296,260 |
| Liabilities and Equity | Accounts payable, accrued liabilities, and other liabilities | 678,687 | 718,509 |
| Liabilities and Equity | Deferred revenue | 1,026,479 | 985,307 |
| Liabilities and Equity | Total liabilities | 12,181,606 | 12,033,567 |
| Commitments and contingencies | Redeemable noncontrolling interests | 27,695 | 159,581 |
| Commitments and contingencies | Common stock, $1.00 par value: 1,500,000,000 shares authorized; 689,465,312 and 695,036,731 shares issued and outstanding | 689,465 | 695,037 |
| Commitments and contingencies | Additional paid-in capital | 13,273,880 | 12,767,914 |
| Commitments and contingencies | Cumulative dividends in excess of earnings | -6,129,129 | -5,952,920 |
| Commitments and contingencies | Accumulated other comprehensive income (loss) | 10,534 | -9,937 |
| Commitments and contingencies | Total stockholders’ equity | 7,844,750 | 7,500,094 |
| Commitments and contingencies | Public investors of Janus Living, Inc. | 979,186 |  |
| Commitments and contingencies | Joint venture partners | 291,294 | 295,455 |
| Commitments and contingencies | Non-managing member unitholders | 355,515 | 347,321 |
| Commitments and contingencies | Total noncontrolling interests | 1,625,995 | 642,776 |
| Commitments and contingencies | Total equity | 9,470,745 | 8,142,870 |
| Commitments and contingencies | Total liabilities and equity | 21,680,046 | 20,336,018 |
